Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
LIN BIOSCIENCE, INC.	6696	Taipei Exchange	370,645	90.4 TWD	Stock
ME LIN STEEL	MEL	HANOI S.E.	556	6,700 VND	Stock
CHEN LIN EDUCATION GROUP HOLDINGS LIMITED	1593	Hong Kong S.E.	438,308	1.49 HKD	Stock
LIN HORN TECHNOLOGY CO., LTD.	5464	Taipei Exchange	207,133	32 TWD	Stock
JIH LIN TECHNOLOGY CO., LTD.	5285	Taiwan S.E.	94,224	66.3 TWD	Stock
ENDLOS INDEXZERTIFIKAT - LUS WIKIFOLIO-INDEX J. K. WEBER INVESTMENT		Börse Stuttgart	-	158.3 EUR	Certificat
A. K. CA 9.3/APR27		Bombay S.E.	-	- %	Bond
A. K. CA 8.0/MAY24		Bombay S.E.	0	107,211 %	Bond
BNP PAR.EHG MINIL LIN		Börse Stuttgart	-	- %	Bond
SG EFF. MINIL LIN		Boerse Frankfurt Warrants	-	- PTS	Certificat

See all

News (758)

Monster Beverage Corporation Commences Modified Dutch Auction Tender Offer to Purchase Up to $3.0 Billion of Its Outstanding Common Stock	05-08	AQ
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision	05-07	BU
TELES Informationstechnologien : Annual Financial Statements 2023	04-30	PU
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations	04-26	PU
Transcript : American Electric Power Company, Inc. - Shareholder/Analyst Call	04-23
Bp : simplifies organisational structure and announces executive team changes - Form 6-K	04-18	PU
Annual General Meeting elects Annette Heimlicher as a new member of the Board of Directors and approves all other proposals	04-17	EQ
AstraZeneca : Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Form 6-K	04-02	PU
JBS S A : MANAGEMENT’S PROPOSAL FOR THE ANNUAL AND EXTRAORDINARY SHAREHOLDERS’ MEETING TO BE HELD ON APRIL 26, 2024 - Form 6-K	03-28	PU
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	03-28	AQ
Globe Life : 2024 Proxy and Shareholder Meeting	03-14	PU
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation	03-13	BU
Huber+Suhner : Compensation Report 2023	03-05	PU
Annette Heimlicher stands for election to the Board of Directors of Komax Holding AG	02-28	EQ
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	02-12	GL
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	02-12	AQ
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization	01-19	BU
Arcadium Lithium plc completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction.	01-03	CI
TELES Informationstechnologien : Annual Financial Statements 2022	12-27	PU
Fubon Financial : FHC Financial Statements(Consolidated) 2023 Q3	12-26	PU
Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer	12-21	PU
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease	12-15	GL
Transcript : SL Green Realty Corp. - Analyst/Investor Day	12-04
AstraZeneca : Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer - Form 6-K	11-17	PU
Bristol Myers Squibb - U.S. Food and Drug Administration Approves Augtyro, a Next-Generation Tyrosine Kinase Inhibitor, for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer	11-16	AQ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)	11-15	BU
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial	11-09	BU
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients	11-02	BU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	23-10-23	PU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	23-10-20	PU
BridgeBio Pharma : BBIO – KRAS Cancers – 2023 AACR-NCI-EORTC – GTP in Active-state KRASG12C Inhibitors	23-10-02	PU
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	23-09-27	PU
PetroChina : 2023 INTERIM REPORT PETROCHINA COMPANY LIMITED - Form 6-K	23-09-20	PU
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®	23-09-19	BU
GBT Technologies : A qualitative study that explores the implementation of artificial intelligence in integrated circuit design - Form 8-K	23-08-28	PU
TeraWulf Announces 7.9 EH/s Expansion Plan and Associated Purchase of 18,500 S19j XP Bitcoin Miners from BITMAIN	23-07-18	GL
Fubon Financial : FHC Financial Statements(Consolidated) 2023 Q1	23-06-30	PU
OPKO HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-06-23	AQ
Caledonia Investments : Proxy Form 2023 AGM	23-06-15	PU
© 2023 Tonix Pharmaceuticals Holding Corp. © 2023 Tonix Pharmaceuticals Holding Corp. TNX - 1700 Gastric and Colorectal Cancers NASDAQ: TNXP Version P0451 June 13 , 2023 (Doc 1243) - Form 8-K	23-06-13	PU
BIOMERICA : InFoods - Jun 2023 General Investor	23-06-11	PU
Oatly : PORTIONS OF INFORMATION CONTAINED IN THIS AGREEMENT HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL - Form 6-K	23-06-01	PU
Bollore : Non-financial performance (Chapter 2/URD 2022 Bolloré)	23-05-12	PU
Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023	23-05-11	BU
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy	23-05-09	PR

1234NextSee all

Companies (323)

ALIMENTATION COUCHE-TARD INC. 53 947 M $

Alimentation Couche-Tard Inc. is engaged in convenience and mobility, operating in about 29 countries and territories, with more than 16,700 stores, of which almost 13,100 offer road transportation fuel. With its Couche-Tard and Circle K banners, the Comp ...

ARTHUR J. GALLAGHER & CO. 55 018 M $

Arthur J. Gallagher & Co. specializes in insurance brokerage services. The group also develops risk management activity. Revenues break down by activity as follows: - insurance and reinsurance brokerage services (85.7%); - risk management and assessment ...

PATEL ENGINEERING LIMITED 566 M $

Patel Engineering Limited is an India-based company, which is engaged in civil engineering and construction of hydro projects, dams, tunnels, roads, railways. It is also involved in real estate activities with owned or leased property. Its power, dams and ...

J&T GLOBAL EXPRESS LIMITED 9 567 M $

J&T Global Express Ltd is a China-based company principally engaged in global logistics services. The Company's businesses include express delivery services, cross-border logistics services, sales accessories and other services. The express delivery servi ...

KESKO OYJ 7 315 M $

Kesko Oyj is the leading wholesaler and retailer in Finland. Net sales break down by family of products as follows: - grocery and convenience goods (53.8%; K-retailer; No. 2 in Finland): owned 1,208 supermarkets and stores under the names K-citymarket, K ...

KESKO OYJ 7 315 M $

NEW ORIENTAL EDUCATION & TECHNOLOGY GROUP INC. 14 439 M $

New Oriental Education & Technology Group Inc is a China-based company mainly engaged in delivering comprehensive educational programs, services and products to students through its nationwide physical network of schools, learning centers and bookstores, ...

DUBAI ELECTRICITY AND WATER AUTHORITY 31 854 M $

Dubai Electricity and Water Authority PJSC is a United Arab Emirates-based utility services provider. The Company distributes electricity and water and serves residential and commercial customers in the United Arab Emirates. The principal activities of th ...

NEW ORIENTAL EDUCATION & TECHNOLOGY GROUP INC. 14 439 M $

1234Next

Insiders

J. K. Lin

J. K. Lin is SVP-Information Technology & Materials Management at Taiwan Semiconductor Manufacturing Co., Ltd. J. K. Lin received an undergraduate degree from National Changhua University of Education.

K. J. Lin

Dennis K. J. Lin

J. K. Delegas

Mr. Delegas, an Associate at Century Capital Partners, joined Century in 2012.
Prior to joining Century, Mr. Delegas was an Analyst in the Investment Banking division of Sandler O'Neill & Partners, working within the Financial Institutions Group.
While at Sandler O'Neill, he focused on mergers and acquisitions and capital raising activities.
Mr. Delegas earned his B.S.
in Finance, summa cum laude, from Babson College.

J. K. Sahu

J. K. Jhanwar

J. K. Dubey

No results for this search